Australian Life Scientist

SECTION

Inside the bacterial machine

Professor Trevor Lithgow is tinkering with the cogs of bacteria to understand how they, and their mitochondrial cousins, tick.

Top Stories

Bionomics launches ovarian cancer trial

Bionomics (ASX:BNO) has commenced a phase I/II trial of its BNC105 compound in ovarian cancer patients.
Turning the immune system on cancer

Researchers from Western Australia have produced a targeted version of a natural protein that can open up cancerous tumours to attack by the body’s own immune system.
Combination therapy protects the brain from malaria infection

Adding a new anti-inflammatory drug to conventional malaria treatments may help prevent irrevocable brain damage associated with cerebral malaria.
Phosphagenics taps Labtec for pain patch design

Phosphagenics (ASX:POH) has enlisted the aid of Germany's Labtec to help design the final version of drug delivery patch TPM/oxycodone, ahead of phase III trials.
Alchemia cancer trial cleared to continue

The DSMB overseeing Alchemia's (ASX:ACL) phase III trial of HA-Irinotecan in metastatic colorectal cancer has recommended that recruitment continue.
Clinuvel starts final trial of Scenesse in EPP

Clinuvel (ASX:CUV) has commenced a final six-month trial of its Scenesse drug in patients with erythropoietic protoporphyria (EPP).
GTG breast cancer test sales gaining pace in US

Melbourne's Genetic Technologies (ASX:GTG) has revealed that its genetic test for breast cancer risk, BREVAGen, is gaining traction in the US.
New biomarker aims at affordable bowel cancer test

Australian researchers have identified genes that can be used to detect the presence of bowel cancer, raising hopes of a new cost-effective blood test.
Opinion: Low scientific literacy impedes public discussion on cancer biomarkers

Translating the discovery of a potential cancer biomarker into a genuine diagnostic is tricky business, but it’s worth persevering, says Clincal Genomics CEO, Dr Lawrence LaPointe.
REVA Medical stent trial shows positive results

Patients enrolled in a pilot trial of REVA Medical's (ASX:RVA) ReZolve coronary stent have so far suffered no major adverse coronary events.
ResMed hunting for new CEO

ResMed (ASX:RMD) is hunting internally and externally for a new CEO to replace founter Dr Peter Farrell when he steps down as CEO at the end of 2013.
Biosceptre, University of Queensland to collaborate on cancer antibodies

Biosceptre and the University of Queensland’s AIBN research institute have teamed up to develop a production method for monoclonal antibodies designed to trigger cancer cell death.
Australian Synchrotron to use Bluechiip tracking tech

The Australian Synchrotron will use a new tracking technology developed by Bluechiip (ASX:BCT) to keep track of samples in extreme temperatures.
Gene patents challenged again

A Labor backbencher has brought the gene patent controversy to the fore once again with a private member’s bill to ban patents on genetic material.
Bioniche burn rate rises on animal health spend

Bioniche (ASX:BNC) revealed its burn rate increased in the March quarter as it stepped up efforts to improve its bottom line through increased animal health sales.
Alchemia gaining US share for anticoagulant

US sales of generic fondaparinux, the anticoagulant produced by Alchemia (ASX:ACL), are expected to have grown 120% year-on-year.